Literature DB >> 32253703

Antigen-specific humoral responses against Helicobacter pylori in patients with systemic sclerosis.

Georgios Efthymiou1, Christos Liaskos1, Theodora Simopoulou1, Emmanouela Marou1, Eleni Patrikiou1, Thomas Scheper2, Wolfgang Meyer2, Dimitrios Daoussis3, Lazaros I Sakkas1, Dimitrios P Bogdanos4.   

Abstract

Helicobacter pylori (Hp) is a likely trigger of systemic sclerosis (SSc), but systemic antigen-specific antibody (Ab) responses in a well-defined cohort of SSc patients have not been thoroughly assessed. Line immunoassay and immunoblotting testing Abs against 15 Hp antigens were performed in 91 SSc patients and 59 demographically matched healthy controls (HCs). Results were validated in an independent cohort of 35 SSc patients. Anti-Hp positivity was detected in 67% SSc patients vs 76.3% HCs. Among anti-Hp (+) individuals, anti-p67-FSH was less frequent in SSc than HCs (p = 0.016), whereas reactivity to the remaining 14 Hp antigens did not differ between patients and HCs. Anti-p67 Abs were less frequent in diffuse cutaneous SSc (dcSSc) compared with HCs (p = 0.018). Anti-p57 and anti-p33 Ab levels were lower in SSc vs HCs (p = 0.007 and p = 0.035, respectively). Anti-p57 and anti-p33 Ab levels were lower in limited cutaneous SSc (lcSSc) (p = 0.010) and dcSSc (p = 0.024), respectively, compared with HCs. Anti-p50 and anti-p17 Ab titers tended to be higher in dcSSc than in lcSSc. Sera from the independent SSc cohort showed comparable results. Anti-VacA Abs were more frequent in pulmonary arterial hypertension (p = 0.042), and anti-p30 Abs were more frequent in calcinosis (p = 0.007), whereas anti-VacA Ab levels were higher in lung fibrosis (p = 0.02). In conclusion, anti-Hp Abs are neither more frequent nor elevated in SSc compared with healthy population, the only exception being the higher frequency and levels of anti-VacA Abs in pulmonary hypertension and lung fibrosis, respectively. These results suggest that Hp is unlikely to be involved in the development of SSc.

Entities:  

Keywords:  Antibodies; Autoantibodies; Autoimmunity; Infection; Scleroderma

Mesh:

Substances:

Year:  2020        PMID: 32253703     DOI: 10.1007/s12026-020-09124-w

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  53 in total

1.  An antibody to VacA of Helicobacter pylori in the CSF of patients with Miller-Fisher syndrome.

Authors:  S Chiba; T Sugiyama; K Yonekura; S Tanaka; H Matsumoto; N Fujii; S Yokota; T Hirayama
Journal:  Neurology       Date:  2004-12-14       Impact factor: 9.910

2.  Helicobacter pylori may be a common denominator associated with systemic and multiple sclerosis.

Authors:  Jannis Kountouras; Christos Zavos; Emmanuel Gavalas; Georgia Deretzi; Panagiotis Katsinelos; Panagiota Boura; Stergios A Polyzos; Ioannis Venizelos
Journal:  Joint Bone Spine       Date:  2011-02-22       Impact factor: 4.929

3.  Prior Helicobacter pylori infection ameliorates Salmonella typhimurium-induced colitis: mucosal crosstalk between stomach and distal intestine.

Authors:  Peter D R Higgins; Laura A Johnson; Jay Luther; Min Zhang; Kay L Sauder; Luz P Blanco; John Y Kao
Journal:  Inflamm Bowel Dis       Date:  2010-10-25       Impact factor: 5.325

4.  Anti-hsp60 antibody responses based on Helicobacter pylori in patients with multiple sclerosis: (ir)Relevance to disease pathogenesis.

Authors:  Georgios Efthymiou; Efthymios Dardiotis; Christos Liaskos; Emmanouela Marou; Vana Tsimourtou; Thomas Scheper; Wolfgang Meyer; Alexandros Daponte; Lazaros I Sakkas; Georgios Hadjigeorgiou; Dimitrios P Bogdanos
Journal:  J Neuroimmunol       Date:  2016-06-23       Impact factor: 3.478

5.  Increased immunoreactivity against human cytomegalovirus UL83 in systemic sclerosis.

Authors:  Emmanouela Marou; Christos Liaskos; Georgios Efthymiou; Efthymios Dardiotis; Alexandros Daponte; Thomas Scheper; Wolfgang Meyer; Georgios Hadjigeorgiou; Dimitrios P Bogdanos; Lazaros I Sakkas
Journal:  Clin Exp Rheumatol       Date:  2017-02-27       Impact factor: 4.473

6.  Study of Helicobacter pylori infection on lung using an animal model.

Authors:  A C Arismendi Sosa; A G Salinas Ibáñez; M V Pérez Chaca; A B Penissi; N N Gómez; A E Vega
Journal:  Microb Pathog       Date:  2018-07-26       Impact factor: 3.738

7.  Seroprevalence of Helicobacter pylori infection in patients with connective tissue diseases.

Authors:  Y Showji; R Nozawa; K Sato; H Suzuki
Journal:  Microbiol Immunol       Date:  1996       Impact factor: 1.955

Review 8.  Infectomics and autoinfectomics: a tool to study infectious-induced autoimmunity.

Authors:  D P Bogdanos; D S Smyk; E I Rigopoulou; L I Sakkas; Y Shoenfeld
Journal:  Lupus       Date:  2015-04       Impact factor: 2.911

9.  Human cytomegalovirus (HCMV) UL44 and UL57 specific antibody responses in anti-HCMV-positive patients with systemic sclerosis.

Authors:  Emmanouela Marou; Christos Liaskos; Theodora Simopoulou; Georgios Efthymiou; Efthymios Dardiotis; Christina Katsiari; Thomas Scheper; Wolfgang Meyer; Georgios Hadjigeorgiou; Dimitrios P Bogdanos; Lazaros I Sakkas
Journal:  Clin Rheumatol       Date:  2017-01-26       Impact factor: 2.980

10.  Helicobacter pylori infection in systemic sclerosis: a systematic review and meta-analysis of observational studies.

Authors:  Wai Chung Yong; Sikarin Upala; Anawin Sanguankeo
Journal:  Clin Exp Rheumatol       Date:  2018-04-16       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.